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Abstract
Purpose Oncologic resections or complications of segmental
femoral prostheses can result in severe bone loss of the femur
for which a total femoral prosthesis (TFP) is required. This
study assesses whether the loss of stability and function caused
by the loss of muscle attachments can be improved by using a
push-through total femoral endoprosthesis (PTTF), because it
saves parts of the femur and its muscle attachments.
Methods In this retrospective case series, ten patients aged
25–77 (mean 54) who received a PTTF between 2005 and
2014 were included for baseline, complications and survival
analysis with a mean follow-up of 5.3 (1.1–9.6) years.
Functional outcome was assessed in six patients using the
Musculoskeletal Tumor Society (MSTS) score, WHO perfor-
mance scale, Toronto Extremity Salvage Score (TESS), SF36,
EQ-5D, NRS pain score, fatigue score and satisfaction score.
Results The mean MSTS score was 64% (23–93%). Five pa-
tients had a WHO performance scale of 1, one patient of 3.
Mean TESS was 69% (13–90%). SF36 was most notably
limited by physical functioning (mean 48), vitality (68) and
general health (67). NRS score was 1.9, 1.8 and 8.3 for pain,
fatigue and satisfaction, respectively. There were four failures:
two infections (one resulting in amputation and one in a minor
revision) and two mechanical failures (which required one
revision to a TFP and one minor revision). Patient survival
was 100%, limb survival 90%, and prosthesis survival 80%.
Conclusion The push-through total femoral endoprosthesis
allows preservation of muscle attachments and offers a good
alternative to total femoral prostheses.
Keywords Push-through . Total femoral prosthesis . Limb
salvaging . Functional outcome . Arthroplasty
Introduction
Overall outcome and survival rates of lower limb malignan-
cies have improved rapidly since the 1970s due to improved
(neo) adjuvant chemotherapy and limb-salvaging procedures
[1–3]. However, the severe femoral bone loss and extensive
soft tissue damage that is associated with limb-salvaging sur-
gery and complications of arthroplasty required the develop-
ment of megaprostheses [3]. The current megaprostheses offer
satisfying results, however, complications such as infection or
dislocation are common [4–8]. Proximal or distal femoral
prostheses outperform total femoral prostheses (TFPs), which
is often attributed to the conservation of the muscle insertions
at the remaining femoral bone [4, 7, 9]. The integrity of the hip
abductors and knee extensors affects the functional result of a
TFP; hip dislocations occur more often after the abductor
muscles are excised [10]. Attempts to fixate these muscles
on the prosthesis have mostly been unsuccessful [9, 11].
The BDurchsteck^—or push-through—total femoral
endoprosthesis (PTTF) (Figs. 1, 2, 3, and 4) distinguishes
itself from the ‘regular’ TFP by connecting the knee compo-
nent to the hip component with an intramedullary metal stem.
This allows preservation of any remaining femoral cortex and
its muscle attachments (Fig. 2), which should increase
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stability and motor control, reduce dislocation rate, allow im-
mediate weight bearing, early rehabilitation and enhance func-
tional outcome.
An analysis of the functional and mechanical performance
of the concept of the PTTF has, to our knowledge, never been
reported. The few reports that mention PTTFs often group them
with TFPs, without assessing this specific concept separately
[12]. This study reports the results of the PTTF and assesses this
concept as a potential alternative to total femur reconstruction.
Materials and methods
Study design
All patients who received a PTTF in two university med-
ical hospitals and one general hospital were included in
this retrospective study. All cases that were identified
were treated between 2005 and 2014. Patients were ex-
cluded if follow-up was ≤one year.
Study procedure
At baseline, patient characteristics, surgical indication (in case
of oncology: oncologic diagnosis and the year of the original
diagnosis) and patient history were obtained. All patients were
asked to fill out the patient reported outcome measures
(PROMs) during a follow-up appointment if no recent ques-
tionnaire was present in the existing database.
Surgical procedure
The surgical approach was subject to variations due to specific
patient history and previous surgeries. A patient specific plan
was made, based on measurements on a recent CT scan. The
patient was positioned in a lateral decubitus position. The hip
was approached via the (postero)lateral approach, which was
extended along the femur, dorsal of the vastus lateralis muscle.
The knee approach was usually midline or anteromedial. In
some cases, two separate incisions were used. After prepara-
tion of the hip and acetabular components, the knee and tibial
components were prepared and placed in situ. A trial reduc-
tion was performed with a trial push-through stem into the
socket. When this construction proved to be stable and in
the right rotation, the definitive prosthesis was assembled
Fig. 1 The concept of the push-through total femoral endoprosthesis and
total femoral prosthesis (Megasystem-C, Waldemar Link GmbH & Co.
KG). a The push-through total femoral prosthesis (PTTF) allows preserva-
tion of muscle attachments on any remaining femoral bone. bExample of a
modular PTTF that preserves the proximal femur. c Example of a total
femoral prosthesis (TFP). The proximal part of the prosthesis usually offers
a way to attach the hip abductors to the prosthesis
Fig. 2 Advantages of the push-through total femoral prosthesis. This
example shows how some of the important hip muscles can be spared
in the case that only the most proximal part of the femur is preserved.
Only the gluteus medius (GMe), gluteus maximus (GMa), piriformis (Pr),
and iliopsoas (Ps) are shown in this example. Others, such as the
quadratus femoris, can be spared as well but are not shown in this image.
This is not possible when using a total femoral prosthesis
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and placed. Patients with severe comorbidity were monitored
post-operatively in the intensive care unit for 24 hours.
Outcome measures
The primary outcome measure is the widely used lower limb
version of the Musculoskeletal Tumor Society (MSTS) score,
which measures functional outcome from the surgeon’s point
of view; it scores pain, function, emotional acceptance, use of
supports, ability to walk and gait on a scale of 0-100% [13].
Secondary outcome measures (PROMS) feature the nu-
meric rating scale (NRS-11) pain score, NRS fatigue score,
NRS satisfaction score, WHO performance status, Toronto
Extremity Salvage Score (TESS), EQ-5D-3 L and SF36 health
survey. The NRS-11 requires patients to rate their level of
pain, fatigue, and satisfaction on a scale from 0 to 10 [14].
The WHO performance status quantifies the patient’s ability
to function in daily life on a scale from 0 (no impairments) to 5
(death) [15]. The lower limb version of the TESS evaluates
physical function and daily activities in patients who suffer
from musculoskeletal tumors, on a scale of 0–100% [16].
The EQ-5D-3L questionnaire (Dutch language, version 1.0)
is a standardized health assessment instrument that scores mo-
bility, self-care, usual activities, pain/discomfort and anxiety/
depression [17]. The Dutch version of the SF36Health Survey
is a validated quality of life questionnaire [18].
Other outcome variables
Peri-operative variables include: duration of surgery, length of
stay (LOS), American Society of Anaesthesiologists (ASA)
score, and complications (infection, bleeding, transfusion re-
quired, thromboembolic events and dislocation).
Patient variables include patient reports, physical examina-
tion and range ofmotion (ROM), survival (and cause of death)
and prosthesis failure. Prosthesis failure is defined according
to the Henderson classification as: complete revision of
endoprosthesis, unplanned revision of a failed part of the pros-
thesis, fixation of a periprosthetic fracture, soft-tissue recon-
struction to improve stability or complete removal of the
endoprosthesis without revision or amputation [19]. It is
subdivided into type: (1) soft-tissue failure, (2) aseptic loos-
ening, (3) structural failure, (4) infection and (5) tumor
Fig. 3 An example of the push-through prosthesis taken one year post-
operatively. a Anterior-posterior radiograph of the pelvis, showing the
proximal PTTF and Exeter cup. The push-through stem provides stability
after several failed osteosynthesis attempts and a vascularised fibula
transplant. b Anterior-posterior radiograph of the left distal femur and
knee. The distal cortex is spared due to the push-through stem. c Lateral
radiograph of the left knee, showing the rotating hinge knee
Fig. 4 An example of the push-through prosthesis taken five years
postoperatively. a Anterior-posterior radiograph of the left hip and
proximal femur. Note how the proximal muscle attachments are
spared. Extra cerclage wires are used to improve post-operative
fixation of the remaining bone. The Link Variocup is used in this
case (hemiarthroplasty). b Lateral radiograph of the rotating-hinge
construction of the PTTF. The distal femur has been replaced with
a modular push-through construction
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progression. Complications and peri-operative data up to the
removal of the prosthesis were included in the analysis.
Statistical analysis
Descriptive statistics were used to describe outcome mea-
sures. The choice was made to use means and ranges for
parametric variables, despite the small sample size, because
means are used in virtually all comparative literature.
Additionally, medians are reported in the outcome table, to
provide a better understanding of the data. Medians with
ranges were used for non-parametric data. All data was proc-
essed using SPSS version 22.
Ethics
The medical ethical committee (METc UMCG) declared that
ethical testing for this study was not necessary, in accordance
with Dutch law. For this type of study formal consent is not
required. All actions related to this research were in accordance
with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
Results
Details on inclusion and exclusion are reported in Fig. 5.
Baseline characteristics are reported in Table 1. Mean age at
surgery was 54 (range 25–77). In seven cases the underlying
pathology was oncologic in nature (Table 1).
A modular Megasystem-C (Waldemar Link GmbH & Co.,
Hamburg, Germany) endoprosthesis was used in eight cases
and a custom made Restoration Modular and MRH/GMRS
(Stryker, USA) endoprosthesis was used in two cases. All
prostheses featured a rotating-hinge knee. The proximal femur
was replaced with the Variocup (Waldemar Link GmbH &
Co., Hamburg, Germany) (hemiarthroplasty) in five cases.
The other five cases received a total hip replacement with a
‘dual mobility’ Avantage (Biomet, Warsaw, Indiana, USA)
cup (3 cases), an Exeter High-wall cup (Stryker, USA) (1
case) and an Exeter Rimfit cup (Stryker, USA) (1 case).
Mean follow-up was 5.3 (1.1–9.6) years.
Primary and secondary outcome
Primary and secondary outcomes are reported in Table 2.
Surgery required 6:33 (4:05–8:46) hours on average. Mean
length of stay was 14 (5–41) days. Mean hip flexion was
87° (45–110°). Mean knee flexion was 88° (40–110°).
During follow-up, there were no radiographic signs of pros-
thesis loosening in any of the cases.
Oncologic outcome
All seven oncologic patients were continuously disease-free
(CDF) at a mean follow-up of 6.3 (1.1–9.6) years.
Complications
There were two infections. Both are described in detail
under ‘Patient and prosthesis survival’. Furthermore, one
case of post-operative bleeding required surgical drainage
of a large haematoma. Transfusion was required in seven
cases due to peroperative blood loss, and in one case to
treat pre-existent anaemia. No thromboembolic events or
hip dislocation occurred.
Patient and prosthesis survival
Patient survival was 100% at a mean follow-up of 5.3 (1.1–
9.6) years. Four prostheses (40%) failed in this series: one of
which required amputation, one required major revision to a
standard TFP, and two required a minor revision.Mean time to
failure was 4.4 (1–9) years.
The first failure was due to infection. A female patient
with severe rheumatoid arthritis underwent a two-stage
revision of her DFP due to loosening, a suspected low-
grade infection with Staphylococcus aureus and a
coincidentally-discovered chondrosarcoma in the femur.
Cultures of tissue samples obtained during implantation
of the custom-made Stryker Restoration Modular PTTF
Failures (prosthesis removal)
excluded from PROMs
N=2
Excluded for other reasons
N=2
Unable to reach, severe
dementia*
FLOWCHART
Fitting inclusion criteria
N=10
Included in baseline and
survival
N=10
Available for MSTS and
PROMs
N=8
Available for follow-up
(MSTS + PROMs)
N=6
Fig. 5 Study flowchart of inclusion and exclusions. *One patient
suffered from severe dementia and therefore was not able to fill out the
PROMs
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were negative. The low-grade periprosthetic infection
with Pseudomonas aeruginosa, which arose after three
years, resulted in surgical debridement and hip disarticu-
lation after five years of suppressive antibiotics.
The second failure was due to the material. The connection
between the MRH knee prosthesis and the custom-made
Stryker Restoration Modular femoral stem broke after almost
three years, during walking. It was revised to a Stryker GMRS
total femoral prosthesis.
The third failure was due to a spontaneous infection, five
years after receiving the Link Megasystem-C PTTF. The
periprosthetic infection was treated with i.v. antibiotics, surgi-
cal debridement of the wound and local gentamicin beads.
Eventually, all polyethylene parts of the PTTF were replaced
and all metal parts were cleaned and re-implanted. Persistent
wound problems required a gastrocnemius flap and skin trans-
plant. The patient is now infection free and doing well, three
years after finishing the antibiotic treatment.
The fourth failure was due to persistent pain after re-
ceiving the Link Megasystem-C PTTF. It was attributed to
unsuccessful adherence of the proximal femoral bone to
the PTTF, an internal rotation contracture and insufficient
anteversion. It was regarded as a structural failure. The
anteversion angle was corrected and the proximal femoral
bone was cemented onto the prosthesis during a minor
revision one year after initial implantation.Ta
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Table 2 Outcome measures
Outcome measure Mean Median Range
MSTS-score (%) 64 68 23–93
NRS-pain 1.9 0 0–5
NRS-fatigue 1.8 0 0–6
NRS-satisfaction 8.3 8.3 6–10
WHO (frequency of occurring) 1(5)–3(1)
TESS (%) 69 79 13–90
EQ-5D 0.774 0.791 0.434–1
SF36
SF36-physical functioning 48 53 0–80
SF36-social functioning 69 75 0–100
SF36-role limit physical 50 50 0–100
SF36-role limit emotional 72 83 0–100
SF36-mental health 75 72 64–88
SF36-vitality 68 70 45–90
SF36-pain 72 79 10–100
SF36-general health 67 65 60–80
SF36-health change 29 25 0–50
MSTS Musculoskeletal Tumor Society score, NRS numeric rating scale,
WHO World Health Organisation performance scale, TESS Toronto
Extremity Salvage Score, EQ-5D-3L EuroQol health-related quality of
life survey, SF36 Short Form 36 health survey. Both the mean andmedian
are listed for variables that usually fit a normal distribution because due to
the small sample size, the mean is sensitive for outliers.
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Discussion
A push-through total femoral endoprosthesis saves part of the
bone and its muscle attachments and most likely preserves its
stability and function better than a TFP. A retrospective analysis
was performed to assess the outcome of the PTTF. All patients
had a long medical history, severe comorbidity and extensive
previous surgeries. All patients survived, but the complication
rate was substantial. Functional outcome varied from severely
impaired to virtually no impairment, however, almost all patients
had relevant disabilities. Emotional functioning, perceived
health and overall quality of life were less impacted and most
patients had little to no pain. Satisfaction with the result of this
procedure was very high. There were no hip dislocations.
Mean MSTS score in this study was 64%, which is com-
parable to mean MSTS scores after primary TFPs (50–73%)
[4, 8, 20]. Secondary TFPs might result in lower MSTS scores
than primary TFPs (60% versus 73%) [10].MSTS scores were
positively influenced by the lack of use of pain medication;
nevertheless, functional impairment and gait decreased the
scores. Individual scores showed great variability (23–93%),
similar to TFP outcome [8, 20]. A similar spread is seen in the
TESS scores (13–90%). Mean TESS scores after TFP range
from 47% to 69% in the literature, with equally large inter-
patient variability [7, 21]. A mean TESS score of 69% after
PTTF is relatively high.
All patients have functional impairments to some degree
after total femoral prostheses; five patients had a WHO perfor-
mance scale of 1 (only limited in heavy exercise) and had an
EQ5D index higher than 0.7. One patient had a WHO perfor-
mance scale of 3 (limited self-care and >50% of the day in bed)
and a lower EQ5D score (0.434). ‘Usual activities’ and ‘mobil-
ity’ impacted the EQ5D index to the greatest extent, while ‘self-
care’, ‘anxiety/depression’ and ‘pain/discomfort’ played a
smaller role. The low levels of pain are also seen in the NRS
pain scores and the SF36 pain sub-scores. Furthermore, four
patients experienced no lasting fatigue after the surgery. Two
patients experienced fatigue but were very satisfied with their
outcome. Many patients mentioned their gratitude for the at-
tempts to spare the leg—as well as the success achieved—and
took the alternative option (amputation) into account in their
satisfaction scores. Satisfaction scores are surprisingly high de-
spite the functional impairment. The SF36 shows impaired
physical functioning (mean 48) and clear limitations (mean
50) due to impaired function. General health perception (mean
67) and perceived vitality (mean 68) show similar scores.
Range of motion plays an important role in the physical func-
tioning of the limb. Mean hip flexion of 87° and knee flexion of
88° after PTTF is higher than after TFP: knee flexion between
60° and 73° (range 0–120°) and hip flexion of 61° has been
reported [4, 22]. The theoretical advantages of preserved muscle
attachments of the PTTF could explain this; nevertheless, more
and other types of studies are necessary to evaluate this.
Complications
In general, complications were comparable to the series by
Clement et al. [5], who reported 19 cases of TFP after
periprosthetic fractures [5].
Our infection rate (20%) is similar to the reported 10–
22% infections after TFP [4–6, 8]. One patient had a pre-
vious infection of her DFP, however, this is not a definite
contraindication [10].
Hip dislocations occur often after TFP (5.3–23%), though
none occurred in our study [5–8, 10]. Our small sample size
could be a factor; however, other factors might explain this.
Excision of the hip abductor muscles increases dislocation
rates of TFPs, something that is averted in the PTTF [7, 10].
Furthermore, all PTTFs were used as secondary limb-
salvaging treatment, which is linked to lower dislocation rates
in TFPs compared to primary limb salvaging TFPs (9% versus
23%) [10]. Additionally, a dual-mobility Variocup and the
Avantage cup were used in most hemiarthroplasties and
THPs respectively, which is known to reduce dislocation rates
in both primary and revision THAs and hemiarthroplasties
[23]. Other studies are necessary to assess these factors.
Aseptic loosening often complicates DFPs, however, im-
plementation of rotating hinge prostheses instead of fixed-
hinge prostheses has reduced this significantly [24]. In this
study only rotating hinge prostheses were used.
Failures
Failure rate in this study is high (40%), although this might
be partly influenced by our broad definition of failure.
Sewell et al. reported five-year TFP survival of 100% con-
sidering removal as the endpoint, which dropped to 56%
with re-operation as endpoint [10]. Our study showed 80%
prosthesis survival and 90% limb-survival, which is very
satisfying given the type of conditions treated. There were
too few patients in our study to draw valid conclusions
about the differences between the Link and Stryker tech-
niques. However, a modular design has the advantage that
it allows the surgeon to adjust to factors that could not have
been foreseen during pre-operative planning.
Patient analysis
It is relevant to note that the lowest functioning patient
was impaired by comorbidity (myocardial infarction,
rheumatoid arthritis, depression) to a far greater extent
than by the outcome of the PTTF, which means her scores
might not accurately reflect PTTF outcome. The patient
with the worst ROM (hip flexion 45°, knee flexion 40°)
previously underwent resection of the knee extensors and
partial reconstruction by transposition of the biceps
femoris muscle during primary oncologic resection and
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patellar resection during revision DFP surgery. All other
patients had a knee and hip flexion of more than 90° in
our study, which is remarkably good.
The two highest functioning patients both were relatively
young, had relatively mild comorbidity and fewer previous
surgical procedures (i.e. less soft tissue damage) than most
other patients. One patient has a job in the food service indus-
try that requires mostly standing and walking for eight hours a
day without problems.
The result of any megaprosthesis will probably im-
prove when patients have had fewer previous surgery;
nevertheless, the push-through prosthesis might have
more to gain than the TFP because it preserves muscle
function while providing the same structural integrity to
the femur (Fig. 2). The analysis seems to suggest that the
PTTF might be suited for patients with limited soft-tissue
damage and sufficient femoral bone stock, while patients
with severe soft-tissue damage (i.e. resection of the exten-
sor apparatus) and comorbidity reap none of the benefits
and might be better off with a TFP. However, larger stud-
ies with longer follow-up will provide more evidence.
Oncologic outcome in the present patients was good
and patient survival was 100%. Studies on TFPs often
report patient survival rates as low as 32–35%, two to five
years after primary tumor resection and limb-salvaging
with a TFP [10, 20]. Recurrent disease occurs less often
after secondary limb-salvaging surgery [10]. All seven
oncologic patients received a PTTF as a secondary treat-
ment because they survived long enough to develop com-
plications of their primary surgery. This inherently selects
patients with favourable oncologic outcome.
This patient selection bias (both PTTFs and TFPs were
used in the study period) is one of the limitations of this
study. Furthermore, the sample size is small because this
prosthesis is rarely used. However, all patients who re-
ceived a PTTF between 2005 and 2014 were included, thus
reducing the sampling bias for PTTF patients. Moreover,
there is no control group with which to compare the find-
ings. Due to the nature of the prosthesis as a ‘last option’
for limb-salvaging there is great heterogeneity among the
patients. The length of the follow-up varies, making it dif-
ficult to note time-dependent changes in the outcome mea-
sures. In spite of these restrictions, this is the first study to
report specifically on the push-through prosthesis.
In summary, patient satisfaction was very high, despite
that functional outcome ranges from severely handicapped
to near-normal functioning. Complication rate was within
the ranges that are reported in the literature. However, no
dislocations occurred. Only one complication resulted in
hip disarticulation. The modular PTTF offers the surgeon
a good alternative to TFP due to its highly patient-specific
approach, preservation of muscle attachments and good
functional outcome.
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